| Cover | Jun. 09, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This amendment is being filed to amend the Current Report on Form 8-K filed by Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") on June 14, 2023 (the "Original Report"). The sole purpose of this amendment is to disclose, as required by the regulations of the Securities and Exchange Commission, Regeneron's decision regarding the frequency of future advisory shareholder votes on executive compensation. No changes have been made to the Original Report. |
| Document Period End Date | Jun. 09, 2023 |
| Entity File Number | 000-19034 |
| Entity Registrant Name | REGENERON PHARMACEUTICALS, INC. |
| Entity Central Index Key | 0000872589 |
| Entity Tax Identification Number | 13-3444607 |
| Entity Incorporation, State or Country Code | NY |
| Entity Address, Address Line One | 777 Old Saw Mill River Road |
| Entity Address, City or Town | Tarrytown |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10591-6707 |
| City Area Code | 914 |
| Local Phone Number | 847-7000 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock – par value $0.001 per share |
| Trading Symbol | REGN |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
